PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
PerkinElmer (PKI) Q3 Earnings Surpass Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 2.03% and 30.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for discovery business and informatics franchise.
Bruker (BRKR) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 24.53% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will PerkinElmer (PKI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks Industry Outlook Highlights Mettler-Toledo, PerkinElmer and Waters
by Zacks Equity Research
Mettler-Toledo, PerkinElmer and Waters have been highlighted in this Industry Outlook article.
3 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), Waters (WAT) and PerkinElmer (PKI) are gaining from strong life science, pharmaceutical and academic end-market demand, as well as rising healthcare spending.
BD's (BDX) New Cloud Software Solution to Boost Lab Workflow
by Zacks Equity Research
BD's (BDX) latest launch is expected to provide scientists with an integrated ecosystem that enables optimization of panel design, collaboration and analysis.
PerkinElmer's (PKI) New Benchtop Platform to Boost Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.
PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance
by Zacks Equity Research
PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.
U.S. Market Faces Worst Meltdown Since 2020: Here's Why
by Indrajit Bandyopadhyay
Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.
PerkinElmer (PKI) Down 11.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Company News for Aug 2, 2022
by Zacks Equity Research
Companies in The News Are: BA, XOM, HSBC, PKI
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results benefit from a solid performance at Discover & Analytics Solutions business.
PerkinElmer (PKI) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 14.29% and 2.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: PerkinElmer (PKI) Q2 Earnings Expected to Decline
by Zacks Equity Research
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Gene Sequencing Stocks With Potential to Gain in 2H22
by Indrajit Bandyopadhyay
Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
PerkinElmer (PKI) Unveils GC Platform to Simplify Lab Operations
by Zacks Equity Research
PerkinElmer's (PKI) newly introduced next-generation, automated GC platform can help simplify lab operations and offer excellent precision for high throughput environments.
PerkinElmer's (PKI) Arm Introduces Two CE-Marked Assays
by Zacks Equity Research
PerkinElmer's (PKI) company launches two CE-marked antibody tests that can support the analysis of the immune response to COVID-19.
PerkinElmer's (PKI) Latest Launch to Expand Food Safety Suite
by Zacks Equity Research
PerkinElmer's (PKI) microbial plates minimize human error by providing standardized protocols and offer a small footprint to save space in incubators and storage areas.
PerkinElmer (PKI) Unveils New NGS System to Aid Genomic Analysis
by Zacks Equity Research
PerkinElmer's (PKI) introduction of the RUO BioQule NGS System is a cost-effective system that can bring improvements in genomic analysis.
Why Is Bruker (BRKR) Up 6.3% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.